Background: Levetiracetam (LEV) is a broad spectrum second-generation antiepileptic drug (AED).
Objective: The objective of the study was to investigate the efficacy and safety of levetiracetam for childhood epilepsies.
Methods: This is single, tertiary centre observational, prospective study, that included paediatric patients who were treated with levetiracetam at Paediatric hospital University Clinical Centre Sarajevo, during the period of 15 years (2008-2022).
Aim To analyse biochemical markers as possible predictors of death before discharge in cooled newborns following perinatal asphyxia. Methods A total of 91 infants that underwent therapeutic hypothermia after perinatal asphyxia were included. Inclusion criteria for therapeutic hypothermia were Sarnat stage 2 or 3.
View Article and Find Full Text PDF